3 results
Approved WMOPending
The central hypothesis of this project is that atorvastatin (added on standard antihypertensive treatment ARB) causes a substantial decrease in MSNA in hypertensive patients with CKD.
Approved WMOWill not start
Primary Objectives:- To assess the efficacy of durvalumab + dCRT compared with placebo + dCRT in all randomized patients based on PFS (per RECIST 1.1 as assessed by BICR)- To assess the efficacy of durvalumab + dCRT compared with placebo + dCRT in…
Approved WMORecruiting
To increase the major pathological response rate (< 10% vital tumor cells) to neoadjuvant treatment by integrating both trastuzumab and pertuzumab into perioperative chemotherapy for HER-2 positive, resectable gastric cancer.